Esophageal cancer (EC) is mostly diagnosed due to clinical symptoms such as dysphagia or anemia. Depending on the staging and the histological subtype, squamous cell carcinoma or adenocarcinoma, patients with non-metastasized disease mostly undergo neoadjuvant chemoradiation or perioperative chemotherapy followed by esophageal resection. Nearly 50% of the curatively treated patients develop distant metastasis within 5 years, although no metastases were clinically evident at time of treatment. More recently, the concept of circulating tumor cells (CTC) has also been introduced for EC. CTC are thought to be the means of systemic tumor spread, with the ability to set up metastases in distant organs. Much effort has been made to capture, enrich and detect these very rare cells from the blood stream of EC patients. CTC have been found to be independent risk factors for worse prognosis in patients with EC. Pre- and intra-therapeutic CTC enrichment and detection has the potential to improve preoperative staging, and provide a differential indication for neoadjuvant therapeutic modality and an indication for adjuvant therapy.

Journal Section:
Review Article
Keywords:
Esophageal cancer, Metastasis, Circulating tumor cells, Liquid biopsy
1.
Krebs in Deutschland, 10. Ausgabe, Robert Koch Institut, Berlin, 2015.
2.
Sudarshan M, Alcindor T, Ades S, et al.: Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Ann Surg Oncol 2015;22:324-330.
3.
Makowiec F, Baier P, Kulemann B, et al.: Improved long-term survival after esophagectomy for esophageal cancer: Influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg. 2013;17:1193-1201.
4.
Hoeppner J, Zirlik K, Brunner T, et al.: Multimodal treatment of locally advanced esophageal adenocarcinoma: Which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients. J Surg Oncol. 2014;109:287-293.
5.
Kulemann B, Liss AS, Warshaw AL, et al.: KRAS mutations in pancreatic circulating tumor cells: A pilot study. Tumour Biol 2016;37:7547-7554.
6.
Reeh M, Effenberger KE, Koenig AM, et al.: Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer. Ann Surg 2015;261:1124-1130.
7.
Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
8.
Li H, Song P, Zou B, et al.: Circulating tumor cell analyses in patients with esophageal squamous cell carcinoma using epithelial marker-dependent and -independent approaches. Medicine (Baltimore) 2015;94:e1565.
9.
Cauley CE, Pitman MB, Zhou J, et al.: Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings. J Am Coll Surg 2015;221:699-707.
10.
Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
11.
van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al.: Staging investigations for oesophageal cancer: A meta-analysis. Br J Cancer 2008;98:547-557.
12.
Van Westreenen HL, Westerterp M, Sloof GW, et al.: Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94:1515-1520.
13.
Anderegg MC, de Groof EJ, Gisbertz SS, et al.: 18F-FDG PET-CT after neoadjuvant chemoradiotherapy in esophageal cancer patients to optimize surgical decision making. PLoS One 2015;10:e0133690.
14.
Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
15.
Ashworth TR: ‘A case of cancer in which cells similar to those in the tumours were seen in the blood after death'. Australian Med J 1869;14:146-147.
16.
Allard WJ, Matera J, Miller MC, et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904.
17.
Alix-Panabières C, Pantel K: Circulating tumor cells: Liquid biopsy of cancer. Clin Chem 2013;59:110-118.
18.
Vona G, Sabile A, Louha M, et al.: Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000;156:57-63.
19.
Gascoyne PR, Noshari J, Anderson TJ, Becker FF: Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 2009;30:1388-1398.
20.
Moon HS, Kwon K, Kim S, et al.: Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab Chip 2011;11:1118-1125.
21.
Nagrath S, Sequist LV, Maheswaran S, et al.: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-1239.
22.
Wicha MS, Hayes DF: Circulating tumor cells: Not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011;29:1508-1511.
23.
Mostert B, Sleijfer S, Foekens JA, Gratama JW: Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009;35:463-474.
24.
Sun YF, Yang XR, Zhou J, et al.: Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 2011;137:1151-1173.
25.
Van der Auwera I, Peeters D, Benoy IH, et al.: Circulating tumour cell detection: A direct comparison between the CellSearch system, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010;102:276-284.
26.
Khoja L, Backen A, Sloane R, et al.: A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508-516.
27.
Giuliano M, Giordano A, Jackson S, et al.: Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 2014;16:440.
28.
Goldkorn A1, Ely B, Quinn DI, et al.: Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32:1136-1142.
29.
Gorges TM, Tinhofer I, Drosch M, et al.: Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012;12:178.
30.
Yu M, Bardia A, Wittner BS, et al.: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-584.
31.
Kulemann B, Pitman MB, Liss AS, et al.: Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas 2015;44:547-550.
32.
Krebs MG, Hou JM, Sloane R, et al.: Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012;7:306-315.
33.
Adams DL, Stefansson S, Haudenschild C, et al.: Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch(®) CTC test. Cytometry A 2015;87:137-144.
34.
Kaifi JT, Kunkel M, Das A, et al.: Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: A prospective trial with different detection techniques. Cancer Biol Ther 2015;16:699-708.
35.
Hofman V, Ilie MI, Long E, et al.: Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: Comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer 2011;129:1651-1660.
36.
Wang S, Du H, Li G: Significant prognostic value of circulating tumor cells in esophageal cancer patients: A meta-analysis. Oncotarget 2017;8:15815-15826.
37.
Sclafani F, Smyth E, Cunningham D, et al.: A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. Clin Colorectal Cancer 2014;13:94-99.
38.
Matsushita D, Uenosono Y, Arigami T, et al.: Clinical significance of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2015;22:3674-3680.
39.
Li H, Song P, Zou B, et al.: Circulating tumor cell analyses in patients with esophageal squamous cell carcinoma using epithelial marker-dependent and -independent approaches. Medicine (Baltimore) 2015;94: e1565.
40.
Hoeppner J, Lordick F, Brunner T, et al.: ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016;16:503.
41.
Liu Z, Jiang M, Zhao J, Ju H: Circulating tumor cells in perioperative esophageal cancer patients: Quantitative assay system and potential clinical utility. Clin Cancer Res 2007;13:2992-2997.
42.
Ikoma D, Ichikawa D, Ueda Y, et al.: Circulating tumor cells and aberrant methylation as tumor markers in patients with esophageal cancer. Anticancer Res 2007;27:535-539.
43.
Kaganoi J, Shimada Y, Kano M, et al.: Detection of circulating oesophageal squamous cancer cells in peripheral blood and its impact on prognosis. Br J Surg 2004;91:1055-1060.
44.
Nakashima S, Natsugoe S, Matsumoto M, et al.: Clinical significance of circulating tumor cells in blood by molecular detection and tumor markers in esophageal cancer. Surgery 2003;133:162-169.
45.
Koike M, Hibi K, Kasai Y, et al.: Molecular detection of circulating esophageal squamous cell cancer cells in the peripheral blood. Clin Cancer Res 2002;8:2879-2882.
46.
Su PJ, Wu MH, Wang HM, et al.: Circulating tumour cells as an independent prognostic factor in patients with advanced oesophageal squamous cell carcinoma undergoing chemoradiotherapy. Sci Rep 2016;6:31423.
47.
Glatz T, Bronsert P, Schäfer M, et al.: Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. Eur J Surg Oncol 2015;41:1300-1307.
48.
Yin XD, Yuan X, Xue JJ, et al.: Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy. Dis Esophagus. 2012;25:750-756.
49.
Tanaka M, Takeuchi H, Osaki Y, et al.: Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer. Esophagus 2015;12:352-359.
50.
Kubisch I, de Albuquerque A, Schuppan D, et al.: Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas. Oncology 2015;89:294-303.
51.
Bobek V, Matkowski R, Gürlich R, et al.: Cultivation of circulating tumor cells in esophageal cancer. Folia Histochem Cytobiol 2014;52:171-177.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.